Chaobo Yin

Background Immunotherapy, including immune checkpoint blockade, has had a major impact on cancer medicine. Nevertheless, many patients do not respond to such therapy. Lack of an interferon (IFN) signature within the tumor correlates with reduced rates of response (1). One approach to overcoming resistance and eliciting a stronger IFN signature is through in situ immunization, which utilizes direct intratumoral injection of immunostimulatory agents designed to enhance the local IFN response.

Caitlin D. Lemke-Miltner, Sue E. Blackwell, Chaobo Yin, Anna E. Krug, Aaron J. Morris, Arthur M. Krieg and George J. Weiner J Immunol March 1, 2020, 204 (5) 1386-1394; DOI: https://doi.org/10.4049/jimmunol.1900742 Key Points Immunostimulation by CMP-001 requires anti-Qβ Ab. In mice, IT CMP-001 induces lymphoma regression that is enhanced by anti–PD-1.

Caitlin D. Lemke-Miltner, Sue E. Blackwell, Chaobo Yin, Anna E. Krug, Aaron J. Morris, Arthur M. Krieg and George J. Weiner J Immunol January 17, 2020, ji1900742; DOI: https://doi.org/10.4049/jimmunol.1900742 Key Points Immunostimulation by CMP-001 requires anti-Qβ Ab. In mice, IT CMP-001 induces lymphoma regression that is enhanced by anti–PD-1.